Connect with us

Featured

Hemp Inc (OTCMKTS: HEMP) Breaking Out as Co Goes Pink Current & Raises New Cultivar that Provides 23.4% Complete Protein

Published

on

Hemp Inc (OTCMKTS: HEMP) one of the original cannabis stocks on the OTC is up over 25% on heavy accumulation after the Company went “pink current” meaning it is compliant with OTCMarkets and can issue press releases to investors. The stock has a long history of making highly explosive moves northbound whenever the sector gets hot making a historic run in 2014 and more recently running from around $0.004 to over $0.04 in early 2021. With Maryland, and Missouri voting to legalize recreational cannabis on November 8, the sector could be getting another push and HEMP should be at the top of speculators watch lists. 

Microcapdaily has been reporting on HEMP for years reporting on November 14, 2014: “HEMP” is making a highly explosive move up with the rest of the sector after hitting a recent low of $0.027. Investors still remember the spectacular run this one made earlier this year from well under a penny to highs of $0.34. Pot stocks are heating up with Marijuana on the ballot in Florida in November. The massive publicity that surrounds such an affect naturally trickles down to the bb’s. The last time HEMP got hot it ran close to 4000% in 5 weeks.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Hemp Inc (OTCMKTS: HEMP) mission is to provide green solutions that help make the world a better place to live. Hemp products are ecofriendly, healthy, and can often replace petroleum-based products. Hemp, Inc. is a pioneer in the industrial hemp industry. Hemp has not been legal in America and other countries for over 70 years. So being able to say “Made from Hemp Grown in the U.S.A.” will be a huge milestone. People want to see change in the world… stop the wars, save the planet from pollution, eat organic, ban GMOs, reduce our carbon footprint, produce green solutions and live healthy lives. Because of all the benefits hemp offers… “Hemp can Revolutionize the World”. With education, people will understand why it’s important to legalize industrial hemp again. The movement towards legalizing hemp is growing.

Hemp, Inc.’s goal is to be the leader in the industrial hemp fiber industry in America, which is now estimated to be over $500 Million. A crop of hemp saves water, energy, reduces the need for pesticides, and is more natural, economical and ecological than using cotton or trees. Hemp, Inc. has one of the largest industrial multipurpose hemp processing facility in North America, an 85,000-square foot facility in Spring Hope, N.C. on 9 acres. Under its wholly owned subsidiary Industrial Hemp Manufacturing, LLC the Company purchased the largest decortication plant in North America and moved it to their facility. 

The controlling shareholders is Bruce Perlowin; he has a colorful history and was the subject of the  #1 most watched CNBC documentary of all time, “Marijuana Inc”. In this interview Bruce shares the latest news from around the country and about Hemp Inc – a publicly traded company he founded to help create a better world.  Mr Perlowin may not have a marketing degree but he has proved himself a master at it getting himself featured in stories and interviews over the years on main stream press including Barrons, The Associated Press, New York Times, Newsweek, Fox News, Wall Street Journal, PBS, Market Watch and NPR among others.

https://twitter.com/GoalSetter7/status/1589337812129939457

To Find out the inside Scoop on HEMP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HEMP

On October 18 HEMP announced it has raised a cultivar of hemp that provides 23.4% complete protein in the fan leaves (the large leaves on the hemp plant). Hemp Inc.’s large fast-growing leaves can be harvested daily and used raw in salads, cooked like spinach, or blended in smoothies. In comparison, soybeans, which are currently thought to be the highest source of complete protein in the plant world, contains only about 18.9% protein, but they also contain estrogen mimicking compounds and compounds that reduce bioavailability (the body’s ability to absorb nutrients). Other protein sources in the plant world are lower in protein and most are not complete proteins.  

The fan leaves can be harvested throughout the growing season and were previously considered a waste material. Far from being a waste material, they can be used fresh or dried to make a whole leaf high protein powder for mixing and cooking. Tons of these valuable leaves may be harvested throughout the growing season without adversely affecting the CBD flower harvest. At this high level of complete protein, the hemp plants can be raised as a greatly beneficial animal feed without the drawbacks found in soybeans.   

The Global leafy fresh vegetable market today is $69.355bn with a Compound Annual Growth Rate (CAGR) of 5.2% estimated from 2022 to 2027. The Global protein supplement market was $20.47bn in December 2021 and is expecting an 8.5% CAGR through 2030.  The US Alternative animal feed market is expected to be $2.85bn by 2027 after a 7.5% CAGR.  

Hemp can be used for industrial uses as well as health uses.  Hemp, Inc. is looking to make a move into the hempcrete market; hempcrete is a carbon-sequestering fibrous insulation material, made from hemp stalk hurd and lime, which was recently approved for the U.S. residential building code, utilized by 49 out of 50 states. HEMP currently has 781,000 pounds of a hemp/kenaf blend of a product that is well suited as a base for hemp/kenaf plastics or oil spill cleanup. In addition, Hemp, Inc. has enough raw hemp/kenaf in stock at Hemp, Inc.’s manufacturing plant in Spring Hope, NC to produce another 770,000 pounds of the hemp/kenaf blend. The kenaf plant looks similar to hemp even though it is a genus of hibiscus. Kenaf can be a key ingredient in the production of hempcrete because it has very similar properties to hemp when used for making plastics, oil spill cleanup, and building materials.   

For More on HEMP Subscribe Right Now!

Currently trading at a $9 million market valuation HEMP OS is 22,782,192,709 shares. The Company has $44 million in assets vs. $30 million in liabilities which has led to significant dilution in the past. But one has to be impressed with HEMP history of explosive moves and its ability to trade millions in dollar volume whenever the sector heats up. Mr. Perlowin has a proven ability at getting himself and HEMP featured in stories and interviews on main stream press. As we said back in 2016 – if pot stocks heat up again HEMP is one to watch. We will be updating on HEMP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HEMP.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HEMP either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Featured

Femasys’ (NASDAQ: FEMY) FemaSeed Receives FDA Nod: A Game-Changer for Infertility Treatment

Published

on

Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration (FDA) has given the thumbs up for the commercialization of FemaSeed, a game-changing option for artificial insemination aiming to boost the natural fertilization process.

FemaSeed:

It’s a breakthrough treatment for infertility, designed to carry sperm right to where conception happens in a woman’s fallopian tube. This breakthrough could change the game in infertility treatments by offering a less invasive option compared to heavy hitters like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), potentially reducing the risk of complications during the procedure.

Kathy Lee-Sepsick, Femasys’ founder and CEO, is beyond excited about the FDA’s green light for FemaSeed. She highlights how this could be a game-changer in providing infertility treatments that are less of a burden. The FDA clearance is a testament to successful teamwork with the FDA and a major step forward in making this new technology available to those struggling with infertility.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The rising numbers of infertility cases in the United States (about 10 million women, as per the Center for Disease Control) show how crucial it is to have accessible and effective infertility treatments. FemaSeed is ready to meet this need by offering an affordable and efficient option for those dealing with infertility.

Here’s an interesting tidbit: FemaSeed works in harmony with FemVue, Femasys’ FDA-cleared diagnostic device. FemVue lets doctors perform an in-office ultrasound assessment of the fallopian tubes, helping diagnose infertility even before going for FemaSeed.

But wait, there’s more! Femasys isn’t just about FemaSeed. They’re also charging ahead with FemBloc, their lead candidate for permanent birth control in late-stage clinical development. Their commitment is to provide accessible solutions for women’s health, covering unmet needs with a range of innovative in-office products.

In a nutshell, Femasys is all about empowering women and couples facing fertility challenges. Their aim? To provide cost-effective and less invasive infertility treatments, backed by innovative diagnostic solutions. With this FDA clearance for FemaSeed, Femasys is a step closer to achieving this mission and leaving a lasting impact in the realm of women’s healthcare.

We will update you on FEMY when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by DigitalMarketingAgency from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.